MoneycontrolMoneycontrol

Neutral Torrent Pharma; target of Rs 4970: Motilal Oswal

น้อยกว่า 1 นาทีในการอ่าน

Motilal Oswal's research report on Torrent Pharma

Torrent Pharma (TRP) delivered slightly better-than-expected revenue/EBITDA (+3%/5%) for the quarter. Earnings were largely in line with estimates due to higher-than-expected tax rate for the quarter. TRP outperformed domestic formulation industry (IPM) growth by a wide margin, led by market share gains in chronic therapies, robust scale-up of Curatio portfolio, and healthy market share in the Semaglutide product. Notably, TRP outpaced the Brazilian branded generics market, led by new launches, volume growth, pricing, and inventory normalization.

Outlook

We value TRP at 52x 12-month forward earnings to arrive at a TP of INR4,970. We remain constructive on TRP's domestic growth prospects, expanding Semaglutide opportunity and potential earnings benefits from JB Pharma integration.

คำจำกัดสิทธิ์ความรับผิดชอบ

อ่านบทความฉบับเต็ม
เข้าถึงบทความจาก Moneycontrol และแหล่งข่าวอื่นๆ ทั้งหมดบน TradingView ได้แบบไม่จำกัด